drugset / Trial / NCT00951132
Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy
Phase 2
Withdrawn
University Hospital, Akershus
AstraZeneca · collabOslo University Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-12
- Completion
- 2013-12
Outcome
Outcome not reported
Stopped: “Failure to include patients”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosuvastatin | Small molecule | 10 mg | — |